GlassScriptPhysician profile
Daniel A Kobrinski
NPI 1255610473
$8,145.32
in general payments reported to CMS, 2019-2025
63 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,280 · 2020: $1,386 · 2021: $276 · 2022: $237 · 2023: $1,844 · 2024: $1,094 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064 · Travel and Lodging: $834 · Education: $67.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.20 |
| Travel and Lodging | $834.35 |
| Education | $67.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $2,600.00 | 2019-2020 | |
| Epizyme, INC. | $1,044.35 | 2023 | Tazverik |
| Pfizer INC. | $718.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $521.26 | 2019-2025 | |
| Janssen Biotech, INC. | $330.58 | 2021-2025 | Rybrevant, Talvey, Darzalex |
| Foundation Medicine, INC. | $213.34 | 2019-2021 | |
| Genentech USA, INC. | $176.99 | 2020-2024 | Polivy, Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $159.12 | 2019-2023 | Vpriv, Fruzaqla |
| Abbvie INC. | $143.52 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $139.53 | 2019-2024 | Imfinzi |
| Daiichi Sankyo INC. | $135.69 | 2019-2024 | Enhertu, Vanflyta, Injectafer |
| Medtronic, INC. | $134.93 | 2023 | Synchromedii |
| Glaxosmithkline, LLC. | $118.77 | 2019-2024 | Ojjaara |
| Genzyme Corporation | $112.47 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $101.88 | 2019-2025 | Keytruda, Reblozyl, Welireg |
Show all 61 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kobrinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.